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ABSTRACT  
Background: To determine the predictive value of cardiac T2* magnetic resonance 
(MR) for heart failure and arrhythmia in thalassemia major. 
Methods and results: We analyzed cardiac and liver T2* MR, and serum ferritin on 652 
thalassemia major patients from 21 UK centers, with 1,442 MR scans. The relative risk 
(95% CI) for heart failure with cardiac T2* values <10ms (compared with >10ms) was 
160 (39, 653).  Heart failure occurred in 47% of patients within one year of a cardiac T2* 
<6ms with relative risk 270 (64, 1129). The area under the ROC curve for predicting 
heart failure was significantly greater for cardiac T2* (0.948) than for liver T2* (0.589, 
P<0.001) or serum ferritin (0.629, P<0.001). Cardiac T2* was <10ms in 98% of scans in 
patients who developed heart failure. The relative risk for arrhythmia with cardiac T2* 
values <20ms (compared with >20ms), was 4.6 (2.66, 7.95). Arrhythmia occurred in 14% 
of patients within one year of a cardiac T2* of <6ms. The area under the ROC curve for 
predicting arrhythmia was significantly greater for cardiac T2* (0.747) than for liver T2* 
(0.514, P<0.001) or serum ferritin (0.518, P<0.001). The cardiac T2* was <20ms in 83% 
of scans in patients who developed arrhythmia.  
Conclusions:  Cardiac T2* MR identifies patients at high risk of heart failure and 
arrhythmia from myocardial siderosis in thalassemia major, and is superior to serum 
ferritin and liver iron. Using cardiac T2* for the early identification and treatment of 
patients at risk is a logical means towards reducing the high burden of cardiac mortality 
in myocardial siderosis. 
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INTRODUCTION 
 
Thalassaemia is the commonest single gene disorder worldwide, with approximately 94 
million heterozygotes for beta thalassaemia and 60,000 homozygotes born each year.1  
Although survival is improving in cohorts of patients in whom deferoxamine was 
introduced at a younger age,2 myocardial siderosis resulting in heart failure remains the 
major cause of death (50-70%) in thalassaemia major patients.2,3 This occurs at a 
strikingly young age with between 15-50% dying by the age of 35 years.2,3  
 
Severe myocardial siderosis causes a toxic dilated cardiomyopathy which can be reversed 
if aggressive chelation is commenced early,4 but clinical diagnosis is often delayed due to 
the typically late onset of symptoms. Catastrophic deterioration in cardiac function 
resulting in death may occur rapidly once clinically obvious heart failure is present. 
Methods for predicting heart failure have been developed based on established measures 
of iron loading, most importantly time averaged serum ferritin >2500µg/L,2,5 and liver 
iron concentration >15mg/kg dry weight,6 but the persistently high mortality rate from 
heart failure indicates that high risk patients are not being identified in time for effective 
intervention to be made. Measurement of ventricular function, such as alteration over 
time in ejection fraction, has also been proposed in thalassemia but it identifies patients at 
a relatively late stage,7 and furthermore, dysfunction may be masked because of 
supranormal left ventricular function in thalassemia patients in the absence of myocardial 
iron loading.8 Most recently, direct assessment of myocardial iron using magnetic 
resonance (MR) relaxation has been used, because iron deposits shorten T1, T2 and T2*. 
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Of these, the measurement of T2* has become the widest used in the heart because it is 
easily combined with cardiac gating, is fast and robust, and the most sensitive to iron 
deposition.9 The cardiac T2* technique is transferrable with good interscanner 
agreement,10 and has now been implemented in at least 50 centers worldwide on 1.5T 
scanners from the three largest scanner manufacturers. Direct calibration of the cardiac 
T2* value to the myocardial iron concentration is reported in animals,11 and in humans.12 
However, whilst this work is important for a complete scientific understanding, the 
relationship between cardiac T2* and prediction of cardiac events can be made 
independently of this data, and in terms of patient care, is the more important. We now 
report the value of cardiac T2* MR to predict cardiac events from a large prospective 
database of thalassaemia major patients, in comparison with the established predictors of 
outcome, liver iron and serum ferritin.  
 
 
METHODS 
Patient population 
A total of 652 patients (1442 scans) with beta-thalassaemia major were included in this 
study. Their clinical care was undertaken at 21 hematology centers throughout the United 
Kingdom, and they were scanned at the Cardiovascular MR Unit of Royal Brompton 
Hospital, London between 1999 and 2006. This is a substantial majority of the UK 
thalassemia major patients (approximately 800 patients), and therefore represents a 
multicentre national sample. Patients were referred for clinical evaluation according to 
local practice at each caring centre, and were unselected. All patients were included in the 
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database, but 17 were excluded from the predictive analysis reported in this study 
because of clinical heart failure (N=11) or arrhythmia (N=6) at the time of first MR scan. 
Of these patients, 319 were male and 333 female with a mean age at time of first scan of 
27.1 ±9.6 years, and detailed patient demographics are shown in table 1. The prospective 
database of all patients was maintained from local patient records, and follow-up was 
completed by local case note review by a single researcher using a standard case record 
form. At the time of analysis, the follow up was complete (100%) for a total of 1285 
patient years. At the time of the first scan, 22 patients were receiving no chelation, having 
had bone marrow transplantation. Of those patients who were treated with chelation, 433 
patients were receiving deferoxamine, 72 patients deferiprone, 105 patients deferoxamine 
combined with deferiprone, 19 patients deferasirox only and 1 patient deferasirox 
combined with deferoxamine. Ferritin levels were recorded within 22.5 ±22.4 days of all 
MR scans. The mean number of blood units transfused per year per patient was 32.6 
±11.5. The prediction of heart failure and arrhythmia in the year after each scan was pre-
defined as the primary endpoint of this study. The holding, follow-up and reporting of the 
results of this database was fully approved by Trent NHS Research Ethics Committee.    
 
Diagnostic criteria 
A diagnosis of heart failure was made only if the patient complained of worsening 
dyspnea at rest or during exercise, and objective left ventricular dysfunction was present 
with an ejection fraction of less than 56%,9,13 and the caring clinician made the clinical 
diagnosis of heart failure. A diagnosis of arrhythmia was made only if the patient 
complained of palpitations, and arrhythmia was objectively demonstrated by 
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electrocardiography using 24 hour monitoring or a standard 12 lead recording. 
Arrhythmias were categorized according to AHA/ACC guidelines,14 and included atrial 
fibrillation (AF) defined as a cardiac arrhythmia arising from the atrium with an atrial 
rate >300 bpm and an irregularly irregular ventricular response in the presence of 
conduction (>10 minutes sustained arrhythmia); supraventricular tachycardia (SVT) 
defined as a tachycardia that emanates from or requires participation of supraventricular 
tissue, other than atrial fibrillation/flutter (>10 minutes sustained arrhythmia); ventricular 
tachycardia (VT) defined as 3 or more consecutive complexes in duration emanating 
from the ventricles at a rate >100/min; and ventricular fibrillation (VF) defined as rapid, 
usually more than 300/min, grossly irregular ventricular rhythm with marked variability 
in QRS cycle length, morphology, and amplitude. Cardiac T2* values >20ms were 
considered normal.9 A liver T2* value of <0.96ms is calibrated to a dry weight equivalent 
of >15mg/g dry weight.9  
 
Magnetic Resonance 
Patients were scanned with a 1.5T scanner (Sonata, Siemens Medical Solutions, 
Erlangen, Germany) using previously reported techniques.15 In brief, cardiovascular MR 
was performed using a cardiac gated, single breath-hold, 8-echo sequence (2.6 – 16.7ms, 
increasing in 2.02ms increments) of a single mid-ventricular short axis slice. A single 
breath-hold, 20 echo sequence (1.07–0.21ms) of a transaxial slice of the liver was also 
acquired. Long axis cines and a contiguous stack of short axis cines were also acquired to 
assess left ventricular dimensions and function using standard techniques.16 Data analysis 
was performed using CMRtools and its plug-in ThalassemiaTools (Cardiovascular 
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Imaging Solutions, London UK) for the liver T2* (a large region of interest excluding 
vascular structures) and heart T2* (a large region of the interventricular septum excluding 
regions in proximity to the coronary veins), as well as left ventricular ejection fraction 
using semi-automated planimetry of endocardial borders.16 All scans were reported at the 
time of acquisition by multiple operators, and a clinical report generated for the referring 
physician. 
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Statistics 
All statistical analysis was performed by the Medical Statistics Department at our 
institution (MR). Many patients in this study had multiple scans and therefore we used a 
mixed-model Poisson regression with nested values (N=1442 scans) to produce 
univariate and multivariate analysis of cardiac T2*, liver T2* and serum ferritin for 
cardiac outcomes, and presented as relative risk (95% confidence intervals). Nesting 
incorporates all data from all scans in the predictive model for cardiac outcomes, and all 
repeated scans from any patient are modeled as non-independent. The unit of analysis 
therefore is each individual scan with the 1 year of follow up the follows it. Scans from 
the same patient are then nested within that patient. Each scan is assessed with regards to 
the outcomes following that individual scan, with the patient entered as a random effect 
to account for within-patient correlation. For purposes of comparison only, the relative 
risks were also calculated for per-scan (non-nested analysis where all scans are 
considered to be independent; N=1442 scans) and for patient first scans only (non-nested 
analysis considering each patient’s first scan only, ignoring any repeated scans; N=652 
scans). These data are shown in supplementary tables as they show similar results to the 
main analysis. Patients were censored from further analysis after a first outcome. All 
patient demographics are presented according to the 1st scan for each patient. The 
distribution of liver T2*, cardiac T2*, ferritin and ejection fraction were not significantly 
deviated from normal by Kolmorogov-Smirnov testing and are therefore presented using 
mean and standard deviation (SD), and presented as per scan. Receiver operating 
characteristic (ROC) graphs were produced for cardiac T2*, liver T2* and serum ferritin 
to compare predictive accuracy for cardiac outcomes across the full range of measured 
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values using the area under the curve. Kaplan Meier curves for time to heart failure and 
arrhythmia were generated. Data with a normal distribution are presented as mean ±SD, 
and those with non-normal distributions are presented as median with the inter-quartile 
range. Statistical significance was set at p<0.05, and all p-values quoted are 2-tailed. All 
analysis was performed using STATA 10.2 (StataCorp, Texas). 
 
RESULTS 
Summary of primary endpoint events 
At 1 year of follow-up, there were 80 episodes of heart failure and 98 episodes of 
arrhythmia. There were 4 deaths, with 3 patients dying from sepsis following bone 
marrow transplant and 1 patient dying following an episode of ventricular tachycardia. 
There were 32 instances where a patient was recorded as having both a heart failure event 
and an arrhythmia event within 1 year of a scan. 
 
Heart Failure 
For the 80 heart failure episodes, 60 presented in New York Heart Association (NYHA) 
class two, 16 were NYHA class three, and 4 were NYHA class four. The mean ejection 
fraction of these 80 patients at the time of diagnosis of heart failure was 43.1 ±7.2%. The 
median (Q1, Q3) time of onset from time of T2* MR scan to an episode of heart failure 
was 158 (52, 342) days. In these heart failure patients, the preceding cardiac T2* was 6.7 
±1.8ms, the liver T2* 3.9 ±3.7ms and ferritin 2,713 ±1,686μg/L. The distribution of 
cardiac T2* values in those patients who went on to develop heart failure in comparison 
with the T2* values of those patients who remained free of heart failure is shown in 
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figure 1a. The relative risks associated with cardiac T2*, liver T2* and ferritin are given 
in table 2. The cardiac T2* was <10ms in 98% of patients who developed heart failure. 
The one year incidence of heart failure in patients with the lowest cardiac T2* of <6ms 
was 47%. In comparison with cardiac T2* values >10ms, there was a significantly 
increased risk of heart failure associated with cardiac T2* values <10ms, with a relative 
risk of 160 (39, 653) in the nested analysis. The relative risk for cardiac T2* <6ms was 
270 (64, 1129). Serum ferritin using the conventional threshold (>2500μg/L) was a 
significant but weaker predictor of heart failure with relative risk 0.56 (0.34, 0.91) vs 
ferritin <2500 μg/L, table 2). Liver T2*<0.96 ms (equivalent to the conventional 
threshold of >15 mg/g/dw iron) was not a significant predictor of heart failure with 
relative risk 0.81 (0.23, 2.80) vs liver T2* >0.96ms.. ROC curves for the prediction of 
heart failure by cardiac T2*, liver T2* and serum ferritin are shown in figure 1b. The area 
under the curve for serum ferritin (0.629) and liver T2* (0.589) were similar (P=0.21), 
but the area under the curve for cardiac T2* (0.948) was substantially and significantly 
greater (P<0.001 vs liver T2*, and P<0.001 vs serum ferritin). The relative risks for the 
first scan only (non-nested) and per scan (non-nested) groups give similar conclusions 
(supplemental table 1). The Kaplan Meier curves for occurrence of heart failure stratified 
into 4 levels of cardiac T2* are shown in figure 1c, and show a significant increase in risk 
with increasing cardiac iron loading (p<0.001). Overall, the T2* threshold of 10ms 
predicted heart failure with a sensitivity of 97.5% (95% CI: 91.3, 99.7) and specificity of 
85.3% (95% CI: 83.3, 87.2). The data was also analyzed for prediction of asymptomatic 
left ventricular dysfunction at the time of the scan, and showed significant incremental 
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relative risk (RR) for each level of cardiac T2* <10ms (T2* 8-10ms RR 2.97; T2* 6-8ms 
3.48; T2* <6ms 4.51; all p<0.001).  
 
Arrhythmia  
For the 98 patients who developed arrhythmias within 1 year of MR scanning, 78 patients 
had AF, 14 patients had SVT, 5 patients had VT, and 1 patient had VF. In these patients, 
at the time of first MR scan, the mean cardiac T2* was 13.5 ±9ms, mean liver T2* 6.0 
±6.4ms, mean serum ferritin 2140 ±1540μg/L, and the mean ejection fraction was 60.7 
±9.3%. The median time to developing arrhythmia was 133 days. The distribution of 
cardiac T2* values in the patients who went on to develop arrhythmia in comparison with 
those who remained arrhythmia free is shown in figure 2a. The relative risks associated 
with cardiac T2*, liver T2* and ferritin are given in table 3. A cardiac T2* of <20ms was 
present in 83% of patients who developed arrhythmia. The incidence of arrhythmia at one 
year in patients with the lowest cardiac T2* of <6ms was 14%. The mean cardiac T2* in 
the arrhythmia patients was: AF 13.6 ±9.9ms, SVT 11.9 ±7.1ms, VT 16.5 ±9.3ms, and 
VF 9.0ms. There was no significant difference between the cardiac T2* values for atrial 
and ventricular arrhythmias (P=0.28). In comparison with cardiac T2* values >20ms, 
there was a significantly increased risk of arrhythmia associated with cardiac T2* values 
<20ms, with a relative risk of 4.60 (2.66, 7.95). The relative risk for a cardiac T2* <6ms 
was 8.79 (4.03, 19.2). There was no significant predictive value using the conventional 
thresholds of ferritin (>2500μg/L) with relative risk 0.90 (0.55, 1.45) vs ferritin 
<2500μg/L) or liver T2* (<0.96ms) with relative risk 0.81 (0.24, 2.74) vs T2* >0.96ms). 
ROC curves for the prediction of arrhythmia by cardiac T2*, liver T2* and serum ferritin 
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are shown in figure 2b. The area under the curve for serum ferritin (0.518) and liver T2* 
(0.514) were similar (P=0.99), but the area under the curve for cardiac T2* (0.747) was 
substantially and significantly greater (P<0.001 vs liver T2*, and P<0.001 vs serum 
ferritin). The relative risks for the first scan only (non-nested) and per scan (non-nested) 
groups give similar conclusions, and are shown in supplemental table 2. The Kaplan 
Meier curves for occurrence of arrhythmia stratified into 3 levels of cardiac T2* are 
shown in figure 2c, and show a significant increase in risk with increasing cardiac iron 
loading (p<0.001). Overall, the T2* threshold of 20ms predicted arrhythmia with a 
sensitivity of 82.7% (95% CI: 73.7, 89.6) and specificity of 53.5%  (95% CI: 50.8 56.2). 
 
 
Effect of MR result on risk 
The reporting of the cardiac T2* value may have caused alterations in treatment which 
could have affected the outcome events. Therefore we analyzed the relative risks for an 
increase or decrease in each chelator (relative to not changing dose), and included these 
in an adjusted analysis looking at heart T2* for prediction of heart failure or arrhythmia. 
There was no statistically significant effect of changing dose, except that an increased 
dose of deferoxamine was associated with a small increased relative risk of arrhythmia, 
and the adjusted relative risk relating heart T2* to outcomes remained very similar to the 
unadjusted ones. Therefore, there is little statistical evidence from the database that short-
term changes in chelation dose after scans altered the ability of T2* to predict outcomes 
over the period of collection of data. 
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Effect of prior history of heart failure or arrhythmia on outcomes 
All patients reported in this study did not have heart failure or arrhythmia at the time of 
first MR scan, but 9 patients had a prior (and resolved) history of heart failure and 1 
patient had a prior (and resolved) history of arrhythmia. Therefore we re-analyzed the 
predictive power of cardiac T2* using prior history of heart failure or arrhythmia as 
covariates, and including in the analysis those patients who developed endpoints within 1 
year of follow-up who had additional MR scans. The relative risk of prior heart failure 
predicting future heart failure was 1.93 (1.19, 3.13), and the relative risk of prior heart 
failure or arrhythmia predicting future heart failure was 1.60 (0.92, 2.81) and 1.59 (0.84, 
3.02) respectively. The relative risk of prior arrhythmia predicting future arrhythmia was 
2.67 (1.41, 5.09), and the relative risk of prior arrhythmia or heart failure predicting 
future arrhythmia was 1.84 (0.86, 3.94) and 2.08 (1.07, 4.02) respectively. There was no 
significant interaction between heart T2* and prior heart failure when looking at heart 
failure, and no significant interaction between heart T2* and prior arrhythmia when 
looking at arrhythmia. Overall therefore, these results show that there were significant 
associations between prior disease and new disease, but these were independent of the 
predictive ability of T2*, and T2* was still a much more powerful predictor. 
 
Regression between iron parameters 
There were significant relationships between all three iron variables (cardiac T2* vs liver 
T2* R2=0.003, p=0.040; cardiac T2* vs ferritin R2=0.003, p=0.041; liver T2* vs ferritin 
R2=0.37, p<0.001). These results should be interpreted in the context of the large sample 
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size (1442) which highly powered to find significant results for regression analysis, and 
on data inspection only the relationship between liver T2* and ferritin is meaningful. 
 
Effect of age, gender and baseline medication on heart failure 
Neither age nor gender were significantly associated with either of the study outcomes 
(p>0.3 in all cases). There was no association between baseline treatment and heart 
failure events either when assessed as a single variable (p>0.2 in all cases) or in 
conjunction with T2* (p>0.4 in all cases).  
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DISCUSSION 
 
Failure to control serum ferritin and liver iron over sustained periods has been linked to 
increased risk of heart disease,2,5,6,7 and other complications of iron overload.17 However 
low values of liver iron or serum ferritin do not necessarily signify low risk of iron 
induced cardiomyopathy.9 This may arise because iron chelation therapy can remove iron 
more rapidly from the liver than from the heart, which may normalize liver iron while 
myocardial iron remains high.9,18,19 Other mechanisms may also be involved, including 
potential genetic variations in function of cardiac iron transport channels, such as the L-
type calcium channel and the divalent metal transporter 1.20,21 Therefore there is often a 
need to identify those patients most at risk of cardiomyopathy even when serum ferritin 
and liver iron values are currently well controlled. While sequential quantification of 
heart function identifies a patient group at increased risk of cardiac mortality,7 it would be 
preferable to identify high risk patients early before cardiomyopathy develops, and use 
targeted treatment.22,23 The estimation of heart iron by MR offers this possibility. This 
has been done using the MR relaxation parameter T2*, which is sensitive to the presence 
of storage iron microaggregates which disturb the homogeneity of the magnetic 
microenvironment. Evidence has been accumulating that low values of cardiac T2*, 
which reflect high cardiac iron levels, are associated with heart failure. In a cross-
sectional study of 28 patients presenting with heart failure, 89% of cases had a cardiac 
T2* <10ms.24 Limited other data has supported this experience.25 In the current study 
therefore, we analyzed our prospective database on all thalassemia major patients living 
in the United Kingdom having a cardiac T2* scan since 1999. The data unequivocally 
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demonstrate that cardiac T2* is a powerful predictor of the subsequent development of 
heart failure. The relative risk was substantial at 270 for the highest risk group with a 
cardiac T2* <6ms in comparison with a cardiac T2* of >10ms. Analysis of the incidence 
of heart failure following the finding of a cardiac T2* of <6ms was impressive with 47% 
of such patients developing this ominous complication within 12 months. The ROC 
analysis showed that the predictive value of cardiac T2* for heart failure was 
significantly and substantially greater than for conventional iron measures for prediction 
of cardiac complications (liver iron, serum ferritin). 
 
The results for prediction of arrhythmia by cardiac T2* are also significant but of lower 
magnitude than for prediction of heart failure. In addition the distribution of cardiac T2* 
in patients presenting with arrhythmia had a greater spread with higher cardiac T2* 
values. However, 83% of cases occurred in patients with cardiac T2* values <20ms, 
indicating myocardial siderosis as the primary cause. The majority of the arrhythmias 
were atrial in origin and these were not dependent on failing ventricular function, as they 
were observed at higher (though still abnormal) T2* levels, than those seen with heart 
failure. The atrial myocardium might be more sensitive to iron deposition than the 
ventricle in the causation of arrhythmias, and this is somewhat supported by historical 
data prior to the use of iron chelators, which suggested that iron deposition is greater in 
the ventricles than the atria.26 Unfortunately T2* measurements of the thin atrial 
myocardium are limited by partial volume effects and are unlikely to be robust, and 
therefore this issue is not easy to address with current non-invasive MR techniques. 
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Thalassemia patients are also susceptible to non-iron dependent causation of atrial 
arrhythmia because of chronically raised cardiac output and atrial dilation.  
 
There are some limitations to our study. We have not formally validated our results in a 
different cohort. However, we have not attempted to build a multivariate model from a 
number of available factors, but looked at a small number of pre-specified iron measures 
and prospectively shown their relation to the outcomes of interest. However, it would still 
be of interest to reproduce these results in another cohort. We used the widely accepted 
normal cardiovascular MR threshold for the lower limit of normality of left ventricular 
ejection fraction of 56% to categorize ventricular dysfunction, although data from a 
single center, which has not been reproduced, suggests that slightly higher threshold 
values may pertain to thalassemia major patients in the absence of cardiac siderosis.27  
 
In conclusion, this study shows that cardiac T2* is highly predictive over 1 year for the 
development of heart failure and arrhythmia, and is significantly more predictive than 
contemporaneous measures of liver iron and serum ferritin. This indicates that the 
inclusion of cardiac T2* assessment in concert with conventional long-term assessments 
of tissue iron loading is mandatory for the comprehensive evaluation of iron loading. A 
widespread program using cardiac T2* in beta-thalassemia major has considerable 
potential to reduce mortality from heart failure by the early identification and treatment 
of patients at risk.28 These data will also be of direct value in management of different 
iron loading conditions such as hemochromatosis and other transfusion dependent 
anemias. 
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Figure Legends 
 
Figure 1 
A)  The frequency distribution of cardiac T2* values in the 80 patients who developed 
heart failure within 1 year of scan (lower panel) in comparison with the other 572 patients 
(upper panel). Note the segregation of cardiac T2* in the patients who went on to develop 
heart failure into the lowest values, such that 98% of patients who developed heart failure 
had a cardiac T2* of <10ms. The solid vertical red line is the median and the dashed red 
lines are the upper and lower quartiles. 
 
B)  Receiver operating characteristic curve for prediction of heart failure within one year 
of MR scanning. The diagonal line shows the performance of a non-diagnostic test. 
Whilst the liver T2* and serum ferritin are weakly predictive, the cardiac T2* is greatly 
superior to both these conventional measures (P<0.001). The points marked on each line 
indicate a threshold of 10ms for cardiac T2*, 0.96ms for liver T2* (equivalent to 
15mg/kg dry weight) and 2500ug/L for serum ferritin.  
 
C)  Kaplan Meier curves showing occurrence of heart failure over 1 year according to 
baseline cardiac T2* values of >10ms, 8-10ms, 6-<8ms, and <6ms (p<0.001). 
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Figure 2 
A)  The frequency distribution of cardiac T2* values in the 98 patients who developed 
arrhythmia within 1 year of scan (lower panel) in comparison with the other 554 patients 
(upper panel). Note the segregation of cardiac T2* in the patients who went on to develop 
arrhythmia into the lowest values, such that 83% of patients who developed arrhythmia 
had a cardiac T2* of <20ms, and also that the cardiac T2* values are higher and wider 
spread than for patients developing heart failure (figure 1). The solid vertical red line is 
the median and the dashed red lines are the upper and lower quartiles. 
 
B)  Receiver operating characteristic curve for prediction of arrhythmia within one year 
of MR scanning. The diagonal line shows the performance of a non-diagnostic test. The 
liver T2* and serum ferritin are not predictive. The cardiac T2* is significantly superior 
to both these conventional measures (P<0.001). The points marked on each line indicate a 
threshold of 10ms for cardiac T2*, 0.96ms for liver T2* (equivalent to 15mg/kg dry 
weight) and 2500ug/L for serum ferritin.  
 
C)  Kaplan Meier curves showing occurrence of arrhythmia over 1 year according to 
cardiac T2* values of >20ms, 10-20ms, and <10ms (p<0.001). 
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Table Legends 
Table 1:  Patient demographics at first MR scan. CI- confidence interval. 
 
Table 2: A) Heart failure relative risks (RR) for increments in cardiac T2* from <6 to 
10ms in comparison with the reference value of T2* >10ms. 
B) Heart failure relative risks for increments in liver T2* from <0.96ms in comparison 
with the reference value of >6.3ms;  
C) Heart failure relative risks for serum ferritin above and below 2500 ug/L. 
 
Table 3: A) Arrhythmia relative risks (RR) for increments in cardiac T2* from <6 to 
10ms in comparison with the reference value of T2* >10ms;  
B) Arrhythmia relative risks for increments in liver T2* from <0.96ms in comparison 
with the reference value of >6.3ms;  
C) Arrhythmia relative risks for serum ferritin above and below 2500 ug/L. 
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Table 1: Demographics 
Total number of patients  652 
Age (years) 27.1 ±9.6 
Sex 
Male 
Female
 
319 
333 
 
Race/ethnicity 
White 
South Asian 
Chinese 
Arabic 
African
 
296 
283 
23 
31 
19 
 
Blood measures: 
Transfusional red blood cell input (mL/kg/year) 
Pre-transfusion hemoglobin (g/dL)
 
113.9 ±49.7 
9.5 ±1.5 
 
Hepatitis C positive 
Yes 
No
 
38 
614 
 
Biochemistry 
Serum ferritin (μg/L) [M: 5-104, F: 4-254 ] 
 
 
2231 ±1801 
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CMR measures: 
Cardiac T2* (ms) geometric mean (95% CI) 
Liver T2* (ms) geometric mean (95% CI) 
LV end diastolic volume index (mL/m2) 
LV end systolic volume index (mL/m2) 
LV ejection fraction (%)
 
19.0 (18.4 – 19.7) 
3.6 (3.5-3.8) 
109 ±112 
43.2 ±21.8 
66.1 ±8.5 
 
 
Chelation (median + Q1,Q3) 
Deferoxamine only (N=433, 66.4%) 
 
Deferiprone only (N=72, 11.0%) 
 
Deferasirox only (N=19, 2.9%) 
 
Deferoxamine & deferiprone (N=105, 16.1%) 
 
 
 
Deferasirox with Deferoxamine (N=1, 0.2%) 
 
 
No Chelation (N=22, 3.4%)
 
202 mg/kg/week (164, 270); 5 days/week (5, 5) 
 
70 mg/kg/day (57, 82)  
 
10 mg/kg/day (7.5, 15)  
 
• Deferoxamine 160 mg/kg/week (111, 235); 4 
days/week (2, 5); 
• Deferiprone 20 mg/kg/day (12, 43.5)  
 
• Deferoxamine 167 mg/kg/week; 5 days/week; 
• Deferasirox 20 mg/kg/day 
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Table 2: Heart failure 
Cardiac T2* No. in No. with Nested Results 
(ms) group heart failure RR 95% CI p 
<6 72 34 270 64 1129 <0.001 
6 to <8 98 29 171 41 718 <0.001 
8 to <10 108 15 81 19 357 <0.001 
10+ 1164 2 1 Reference   
              
Liver T2* No. in No. with Nested Results 
(ms) group heart failure RR 95% CI p 
<0.96 63 3 1.25 0.33 4.76 0.74 
0.96 to <1.4 136 14 2.59 1.16 5.79 0.021 
1.4 to <2.7 382 26 1.68 0.85 3.31 0.13 
2.7 to <6.3 484 22 1.22 0.61 2.45 0.57 
6.3+ 377 15 1 Reference  
              
Ferritin No. in No. with Nested Results 
μg/L group heart failure RR 95% CI p 
2500+ 450 35 0.56 0.34 0.91 0.02 
<2500 992 45 1 Reference   
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Table 3: Arrhythmia 
Cardiac T2* No. in No. with Nested Results 
(ms) group arrhythmia RR 95% CI p 
<6 72 14 8.79 4.03 19.2 <0.001 
6 to <8 98 20 7.5 3.71 15.2 <0.001 
8 to <10 108 16 6.82 3.28 14.2 <0.001 
10 to <15 263 21 3.23 1.65 6.3 0.001 
15 to <20 165 10 2.21 0.97 5.02 0.058 
20+ 736 17 1 Reference   
              
Liver T2* No. in No. with Nested Results 
(ms) group arrhythmia RR 95% CI p 
<0.96 63 3 0.82 0.23 2.96 0.77 
0.96 to <1.4 136 10 1.21 0.54 2.69 0.64 
1.4 to <2.7 382 28 1.13 0.64 2 0.68 
2.7 to <6.3 484 27 0.83 0.48 1.46 0.52 
6.3+ 377 30 1 Reference   
              
Ferritin No. in No. with Nested Results 
μg/L group arrhythmia RR 95% CI p 
2500+ 450 30 0.9 0.55 1.45 0.65 
<2500 992 68 1 Reference   
 
 
 
 
 
 
 
 
 
Cardiac T2* and cardiac complications Page 33 Kirk et al, CIRCULATIONAHA/2009/874487 
 
 
 
 
 
 
 
 
